A Phase 1 clinical trial that uses the gene editing tool CRISPR to engineer multiple myeloma cellular immunotherapy will soon…
Articles by Magdalena Kegel
The first patient has been dosed in a Phase 1 trial of P-BCMA-101, a new, more powerful type of CAR…
Patients with relapsed or refractory multiple myeloma who are treated with new therapy combinations remain on their treatments far shorter…
Newly diagnosed multiple myeloma patients respond better to treatment when Empliciti (elotuzumab) is added to a combination of…
BioLineRx has launched a Phase 3 trial to assess if adding BL-8040 to standard treatment will improve the outflux…
Weighing individual cancer cells could help doctors predict how multiple myeloma patients will respond to treatments, a Massachusetts Institute of…
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell…
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume,…
Poseida Therapeutics is developing CAR T-cell therapies that can get rid of cancer-generating bone marrow cells before a blood…
Janssen plans to share new data from Phase 3 trials of Darzalex (daratumumab) for multiple myeloma at the 59th American…